Amgen vs Oracle: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Oracle was founded in 1977 by Lawrence Joseph Ellison, Robert Nimrod Miner, Edward A. Oates and is led by Clay Magouyrk and Mike Sicilia.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Oracle
Lawrence Joseph Ellison
Oracle possesses arguably the most aggressive, intensely competitive, and controversial founding story in the entire history of Silicon Valley, rooted entirely in a CIA contract and driven by arguably the most competitive billionaire in American business histo…
Robert Nimrod Miner
Bob Miner co-founded Oracle and served as the central technical architect behind the company's early database products. While Ellison drove sales and strategy, Miner focused on making the software work for demanding customers.
Edward A. Oates
Ed Oates co-founded Oracle in 1977 and played an important role in the company's early technical and product formation. He helped the young company take relational database concepts and present them in an usable, commercially credible way.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Oracle
- Larry Ellison1977–present
Co-founder, Chairman and Chief Technology Officer
As the legendary Founder and CTO, he maintains absolute, tyrannical control over the company's strategic direction, fiercely driving its massive pivot toward cloud computing and artificial intelligence.
Source - Safra Catz2014–2025
Executive Vice Chair (CEO 2014-2025)
Served as co-CEO from 2014 and sole CEO from 2019 until September 2025, when she became executive vice chair of the board.
Source - Hilary Maxson2021–present
Chief Financial Officer
She brings critical global financial expertise to the board's massive capital allocation strategies.
Source - Clay Magouyrk2025–present
Co-Chief Executive Officer
Previously president of Oracle Cloud Infrastructure, where he led the OCI build-out from its early engineering team. Named co-CEO on September 22, 2025 with responsibility tied to Oracle's AI infrastructure expansion.
Source - Mike Sicilia2025–present
Co-Chief Executive Officer
As Executive Vice President of Global Industries, he manages Oracle's massive push into highly specialized vertical software markets, particularly focusing on healthcare and telecommunications.
Source
Timeline: Amgen and Oracle side by side
1977Oracle
Oracle Founded
Larry Ellison, Bob Miner, and Ed Oates founded the company that became Oracle.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1986Oracle
Oracle IPO
Oracle went public on the Nasdaq in March 1986.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1994Oracle
Acquired Rdb
Oracle acquired Rdb in 1994.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2005Oracle
Acquired PeopleSoft
Oracle acquired PeopleSoft for $10.3 billion. Oracle acquired PeopleSoft to significantly expand its enterprise applications portfolio and compete more directly with SAP.
2008Oracle
Acquired BEA Systems
Oracle acquired BEA Systems for $8.5 billion. Oracle acquired BEA Systems to strengthen middleware, application server, and enterprise integration capabilities.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2010Oracle
Sun Microsystems Acquisition
Oracle acquired Sun Microsystems, adding Java, Solaris, and hardware assets.
2014Oracle
Ellison Steps Down as CEO
Larry Ellison stepped down as chief executive in September 2014, and Mark Hurd and Safra Catz became co-CEOs.
2016Oracle
Acquired NetSuite
Oracle acquired NetSuite for $9.3 billion. Oracle acquired NetSuite to strengthen its cloud-native ERP portfolio and reach mid-sized companies that were not ideal buyers for Oracle's traditional enterprise applications.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2022Oracle
Cerner Acquisition Completed
Oracle completed the Cerner acquisition and expanded into healthcare data systems.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Oracle
Clay Magouyrk and Mike Sicilia Named CEOs
Oracle promoted Clay Magouyrk and Mike Sicilia to Chief Executive Officers; Safra Catz became Executive Vice Chair.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Oracle
$67.357B FY2026 Revenue
Oracle reported record FY2026 total revenue of $67.357 billion.
2026Oracle
Q1 FY2027: $664B RPO
Oracle reported Q1 FY2027 revenue of $19.3B and RPO of $664B, and completed a $20B at-the-market common stock sale.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Oracle
- Cerner2022$28.3B
- NetSuite2016$9.3B
- Sun Microsystems2010$7.4B
- BEA Systems2008$8.5B
- Hyperion Solutions2007$3.3B
- Siebel Systems2006$5.8B
Questions about Amgen vs Oracle
Who is the CEO of Amgen Inc. and Oracle Corporation?
Amgen Inc. is led by Robert A. Bradway and Oracle Corporation is led by Clay Magouyrk and Mike Sicilia. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Oracle Corporation?
Oracle Corporation was founded in 1977 — 3 years before Amgen Inc., which was founded in 1980. Oracle Corporation's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to Oracle Corporation?
Amgen Inc. employs approximately 31,500 people, while Oracle Corporation employs approximately 141,000. Oracle Corporation has the larger workforce at 141,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Oracle Corporation headquartered?
Both Amgen Inc. and Oracle Corporation are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Oracle Corporation?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Oracle Corporation was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, Edward A. Oates.
Which company has a longer operating history — Amgen Inc. or Oracle Corporation?
Oracle Corporation has been operating for approximately 49 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Oracle overview